FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

|--|

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* RICHMOND TIMOTHY J.					2. Issuer Name and Ticker or Trading Symbol AbbVie Inc. [ABBV]								(Ched	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) EVP, Chief HR Officer						
(Last) (First) (Middle) 1 N. WAUKEGAN ROAD						3. Date of Earliest Transaction (Month/Day/Year) 11/27/2020													- X	
(Street) NORTH CHICAGO IL 60064 (City) (State) (Zip)					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	S. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,		Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			4 and Securiti Benefic		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code	v	Amount	(A) (D)	or P	rice	Transact	Transaction(s) (Instr. 3 and 4)			,			
Common Stock, \$0.01 par value 11/27/				7/202	2020			М		51,99) A	. \$	\$51.42		1,990		D			
Common Stock, \$0.01 par value 11/27/				7/202	2020			S		51,990	0 [\$105	0			D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,		ansaction ode (Instr.		of		6. Date Exercisal Expiration Date (Month/Day/Year		7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		urity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	Own For Illy Dire or li (I) (I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	ble [Expiration Date	Title	or Nur of	mber ares						
Option (Right to buy) ⁽¹⁾	\$51.42	11/27/2020			M			51,990	02/20/20	15 (02/19/2024	Commo	51,	,990	\$0	0		D		

Explanation of Responses:

1. Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

This transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1(c).

Steven L. Scrogham, attorneyin-fact for Timothy J.

12/01/2020

Richmond

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.